A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferipron-desferrioxamine versus deferasirox

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferipron-desferrioxamine versus deferasirox

Bibliographic Details
Main Authors:	Borgna-Pignatti Caterina, Restaino Gennaro, Salvatori Cristina, Cianciulli Paolo, Capra Marcello, Filosa Aldo, D'Ascola Domenico G, Dell'Amico Maria, Rossi Giuseppe, Meloni Antonella, Pepe Alessia, Lombardi Massimo
Format:	Article
Language:	English
Published:	BMC 2011-02-01
Series:	Journal of Cardiovascular Magnetic Resonance

Similar Items

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
by: Capra Marcello, et al.
Published: (2011-02-01)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy
by: Maggio Aurelio, et al.
Published: (2011-02-01)

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
by: Ricchi Paolo, et al.
Published: (2011-02-01)

ANALYSIS OF DEFERASIROX AND DEFERIPRON USE IN CHILDREN WITH PEDIATRIC -THALASSEMIA MAJOR
by: Evy Sari Sutrisnaningsih, et al.
Published: (2017-08-01)

The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Mohammad Ali Mashhadi, et al.
Published: (2011-06-01)

The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Ebrahim miri moghaddam, et al.
Published: (2011-04-01)

Assessment of the effect of combination therapy with Deferiprone & Desferrioxamine on cardiac complications in major Thalassemia
by: F. Rashidi ghader, M.D, et al.
Published: (2007-01-01)

Pharmacokinetic study of deferiprone and deferasirox with different treatment regimens in Taiwanese thalassemia patients
by: Ta-Shu Song, et al.
Published: (2014)

Myocardial fibrosis by delayed enhancement cardiovascular magnetic resonance and HCV infection in thalassemia major patients
by: Quarta Antonella, et al.
Published: (2010-01-01)

Analysis deferoxamine, deferiprone, and deferasirox in β-thalassemia patients’ plasma by capillary electrophoresis and copper nanoclusters
by: Hung-Ju Lin, et al.
Published: (2017)

Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major
by: Hossein Karami, et al.
Published: (2017-01-01)

Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report
by: Pustika Amalia Wahidiyat, et al.
Published: (2018-06-01)

Efficacy and Side Effects of Deferasirox and Deferiprone for Thalasemia Major in Children
by: Asti Y. Rindarwati, et al.
Published: (2016-12-01)

Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
by: Sujian Xia, et al.
Published: (2013-01-01)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
by: Shahla Ansari, et al.
Published: (2017-06-01)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
by: Taher AT, et al.
Published: (2016-12-01)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
by: Kontoghiorghe CN, et al.
Published: (2016-01-01)

Preferential patterns of myocardial iron deposit by multislice multiecho T2* CMR in thalassemia major patients
by: Ciancio Angela, et al.
Published: (2010-01-01)

Diabetes mellitus and cardiac complications in thalassemia major patients
by: Pepe Alessia, et al.
Published: (2012-02-01)

Myocardial iron overload in sickle/thalassemia patients of Italian origin
by: Meloni Antonella, et al.
Published: (2013-01-01)

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
by: Nancy F Olivieri, et al.
Published: (2019-01-01)

Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone
by: Viktor A. Timoshnikov, et al.
Published: (2021-08-01)

DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
by: Ali Taher
Published: (2018-11-01)

Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.
by: PLOS ONE Staff
Published: (2019-01-01)

Different patterns of myocardial iron overload by multislice T2* Cardiovascular MR as markers of risk for cardiac dysfunction in thalassemia major
by: Lombardo Massimo, et al.
Published: (2011-02-01)

Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients
by: Nargesbeygom Mirbehbahani, et al.
Published: (2015-01-01)

Side effect of deferiprone as iron chelator in patient with thalassemia
by: Mikhael Yosia, et al.
Published: (2018-01-01)

A Study of Knowledge about Deferasirox and Behavior of Taking Deferasirox in Patients with β-Thalassemia Major
by: Pei-Yi Mei, et al.
Published: (2012)

Deferiprone-induced arthropathy in thalassemia: MRI findings in a case
by: Gyan Chand, et al.
Published: (2009-04-01)

Treating thalassemia major-related iron overload: the role of deferiprone
by: Berdoukas V, et al.
Published: (2012-10-01)

Efficacy of defroxamine- deferiprone on cardiac function of patients with major thalassemia
by: Mirbehbahani NB, et al.
Published: (2015-09-01)

THE ANTIOXIDANT EFFECTS OF CAPPARIS OVATA AND DEFERASIROX IN PATIENTS WITH THALASSEMIA MAJOR
by: Duran Canatan, et al.
Published: (2014-08-01)

THE ANTIOXIDANT EFFECTS OF CAPPARIS OVATA AND DEFERASIROX IN PATIENTS WITH THALASSEMIA MAJOR
by: Handan Duman, et al.
Published: (2014-08-01)

T2* heterogeneity detected by CMR could be related to myocardial iron distribution in Thalassemia patients
by: Landini Luigi, et al.
Published: (2009-01-01)

Cataract Formation due to use of Deferiprone in a Patient with Thalassemia Major
by: Barbaros sahin Karagun, et al.
Published: (2015-03-01)

Urinary Metabolic Profile of Patients with Transfusion-Dependent β-Thalassemia Major Undergoing Deferasirox Therapy
by: Giovanna Capolongo, et al.
Published: (2020-05-01)

MRI assessment of correlation between cardiac biventricular function, myocardial iron overload and pancreatic iron overload in a large cohort of thalassemia major patients
by: Luciani Antongiulio, et al.
Published: (2010-01-01)

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
by: Ricchi P, et al.
Published: (2015-12-01)

Protective action of deferiprone and deferoxamine in erythrocytes isolated from patients with β-thalassemias
by: Alisson F. Santos, et al.
Published: (2009-01-01)

Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia
by: Murtadha Al-Khabori, et al.
Published: (2013-03-01)

Cannot write session to /tmp/vufind_sessions/sess_i5dfk7dv4bkc1pi6620lia2v74